Syncona 新闻与活动
在场
是其中之一......
Syncona 是一家在股票代码 SYNC (GB) 下上市的公司。
Syncona 在 3 个国家有直接业务。Syncona 拥有 13家子公司，其中包括 Achilles Therapeutics、Anaveon 和 Autolus Therapeutics。
他们在：
高管
查看带有其 218 名主要高管的组织结构图
Syncona 搜索最多的简介
- Chris Hollowood, Chief Executive Officer
- Julie Cherrington, Non-Executive Director
- Gian Piero Reverberi, Non-Executive Director and Chair of the Remu...
高管在Syncona变化
- John RocheJohn Roche 将于202410月1作为 Non-Executive Director 加入公司 (新闻发布的2024九月20号).
创建提醒
跟踪 Syncona 的高管变动
控股公司
Syncona 拥有 1,335 家竞争者，其中包括 Berkshire Hathaway (美国(美洲))、HPS Investment Partners (美国(美洲)) 和 Tata Sons (印度)。
Popular M&A news in 控股公司
- Raptor Partners and FNB have announced they will merge (公布2025四月11号)..
- Abrdn的新名称是Aberdeen Group。 (公布2025三月13号).
- Bridgepoint 已收购 Energy Capital Partners (公布2025三月10号).
控股公司 行业的其他推荐联系人
消息
Syncona 的最新新闻稿
- Anaveon appoints Dr. Richard Sachse as Chief Medical Officer
- iOnctura reaches new clinical milestones in uveal melanoma
- Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
- Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis
- Insights & articles
- Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP)
- Creating Yellowstone – Syncona’s launch team in action
- Spur Therapeutics Announces Development Candidate in Parkinson’s Disease Gene Therapy Program
- Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain
- Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel - obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
- View more press releases Close
